Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 1,220,000 shares, a decline of 7.6% from the August 15th total of 1,320,000 shares. Based on an average daily trading volume, of 107,400 shares, the days-to-cover ratio is currently 11.4 days. Currently, 6.8% of the company’s shares are sold short.
Hedge Funds Weigh In On Aura Biosciences
Hedge funds and other institutional investors have recently modified their holdings of the company. Matrix Capital Management Company LP acquired a new position in Aura Biosciences during the 4th quarter worth approximately $69,837,000. Citadel Advisors LLC acquired a new position in Aura Biosciences during the 4th quarter worth approximately $37,318,000. Adage Capital Partners GP L.L.C. acquired a new position in Aura Biosciences during the 4th quarter worth approximately $21,318,000. FMR LLC lifted its position in Aura Biosciences by 22.1% during the 2nd quarter. FMR LLC now owns 603,471 shares of the company’s stock worth $8,551,000 after acquiring an additional 109,362 shares in the last quarter. Finally, Nantahala Capital Management LLC lifted its position in Aura Biosciences by 13.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 343,215 shares of the company’s stock worth $4,863,000 after acquiring an additional 41,225 shares in the last quarter. 53.96% of the stock is owned by institutional investors and hedge funds.
Aura Biosciences Stock Up 0.6 %
NASDAQ AURA opened at $15.05 on Tuesday. Aura Biosciences has a 1-year low of $11.98 and a 1-year high of $26.16. The business’s 50-day simple moving average is $14.97 and its 200-day simple moving average is $16.51.
Analyst Upgrades and Downgrades
Aura Biosciences Company Profile
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.